



Please type a plus sign (+) inside this box →

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Receipt

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

	Application Number	10/056,680
	Filing Date	January 25, 2002
	First Named Inventor	Teddy Kosoglou et al.
	Group Art Unit	1743
	Examiner Name	To be Assigned
5	Attorney Docket Number	CV01492K

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Request for Corrected Filing Receipt (2 pgs)
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	<input type="checkbox"/> Copy of Filing Receipt (2 pgs)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> Return Postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Ann M. Cannoni (Reg. No. 35972)
Signature	
Date	TC 1700 APR 9 - 2002 March 25, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 3/25/02

Typed or printed name	Ann M. Cannoni (Reg. No. 35972)
Signature	
Date	3/25/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



CASE: CV01492K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Teddy Kosoglou *et al.*

: Examiner: To Be Assigned

For Patent For:

Combinations of Sterol Absorption
Inhibitor(s) with Blood Modifier(s) for Treating
Vascular Conditions

: Group Art Unit: 1743

Serial No.: 10/056,680

: Date: March 25, 2002

Filed: January 25, 2002

:

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Assistant Commissioner for Patents
Washington, D.C. 20231

**ATT: APPLICATION PROCESSING DIVISION'S
CUSTOMER SERVICE CENTER**

REQUEST FOR A CORRECTED FILING RECEIPT

Sir or Madam:

This is a request for issuance of a corrected Filing Receipt in the above-identified application. Applicants advise the Filing Receipt (copy enclosed) cite "modifiers(s)" and "indications" in the title, please correct this misspelling to "modifier(s) and "conditions". The title should therefore read "Combinations of Sterol Absorption Inhibitor(s) With Blood Modifier(s) For Treating Vascular Conditions".

Applicants request that a corrected Filing Receipt be issued.

Respectfully submitted,

Ann Marie Cannon
Ann Marie Cannon
Re. No. 35,972
Agent for Applicants
(908) 298-5024

RECEIVED
APR 9 - 2002
TC 1700

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to the Assistant
Commissioner for Patents, Washington, D.C. 20231
on March 25, 2002


Ann Marie Cannon
Registered Representative

An Marie
Signature

3/25/02

Date of Signature

Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/056,680 ✓	01/25/2002 ✓	1743	1244	CV01492K✓		48 ✓	3

CONFIRMATION NO. 9993

24265
SCHERING-PLough CORPORATION
PATENT DEPARTMENT (K-6-1, 1990)
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033-0530

FILING RECEIPT



OC00000007505241

Date Mailed: 02/21/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Teddy Kosoglou, Jamison, PA; ✓
Rudyard J. Ress, Flemington, NJ; ✓
John T. Strony, Lebanon, NJ; ✓
Enrico P. Veltri, Princeton, NJ; ✓

PATENT DEPARTMENT RECEIVED
FEB 27 2002

ROUTE TO COMMENTS *[Handwritten signature]*

<input type="checkbox"/> COMPUTER INPUT
<input type="checkbox"/> BZA
<input type="checkbox"/> DEBIT NOTE ENTERED
COMPLETED BY <i>[Signature]</i>

Assignment For Published Patent Application

Schering Corporation;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/324,123 09/21/2001
AND CLAIMS BENEFIT OF 60/264,396 01/26/2001 ✓
AND CLAIMS BENEFIT OF 60/264,600 01/26/2001 ✓
AND CLAIMS BENEFIT OF 60/264,275 01/26/2001 ✓

Foreign Applications

If Required, Foreign Filing License Granted 02/20/2002

Projected Publication Date: 08/01/2002

Non-Publication Request: No

Early Publication Request: No

RECEIVED
APR 9 - 2002
TC 1700

Title

Combinations of sterol absorption inhibitor(s) with blood-modifiers(s) for treating vascular
-indications
↑ CONDITIONS MODIFIER(S)

Preliminary Class

436

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).